RxDoctor Payments Data

Adnan Yunus, MD

Geriatric Medicine · Bronxville, NYNPI 1174843213

Payments from drug & device makers

$910in general payments, 2019–2025

Across 42 payments — averaging $21.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$208
  • Mylan Specialty L.p.$125
  • Amarin Pharma, Inc.$104
  • Novartis$90
  • Amneal Pharmaceuticals LLC$70
  • AbbVie$66
  • plus $247 from 10 others

What the payments were for

  • Food & beverage$89598%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$910 in reported general payments places this provider in the 80th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$223,418
Medicare patients
385
Services billed
2,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban220$77,867
JardianceEmpagliflozin36$29,424
JanuviaSitagliptin Phosphate35$26,516
TrulicityDulaglutide28$19,915
EntrestoSacubitril/Valsartan31$10,661
XareltoRivaroxaban20$9,583
AbrysvoRsv Vacc, Pref A And Pref B/Pf27$9,376
SantylCollagenase Clostridium Hist.21$8,465
Memantine Hcl203$8,293
Risperdal ConstaRisperidone Microspheres12$7,839
Budesonide29$6,648
Breo ElliptaFluticasone/Vilanterol11$6,322
TradjentaLinagliptin17$4,486
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam34$4,403
Enoxaparin Sodium30$4,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$53$87,242247 claims
Boehringer IngelheimJardiance, Tradjenta$208$33,90953 claims
Johnson & JohnsonXarelto, Risperdal Consta$33$17,42232 claims
NovartisEntresto$90$10,66131 claims
GSKBreo Ellipta$12$6,32211 claims
Astellas Pharma US IncMyrbetriq$19$4,03013 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$70$3,014256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in Bronxville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →